Next Article in Journal
Relationship between Antioxidant and Anticancer Activity of Trihydroxyflavones
Next Article in Special Issue
Nanotechnology for Cancer Therapy Based on Chemotherapy
Previous Article in Journal
Response of Ustilago maydis against the Stress Caused by Three Polycationic Chitin Derivatives
Previous Article in Special Issue
Novel Anti-Tuberculosis Nanodelivery Formulation of Ethambutol with Graphene Oxide
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessReview
Molecules 2017, 22(12), 2167;

The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats

Department of Small Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, 02-776 Warsaw, Poland
Author to whom correspondence should be addressed.
Received: 7 November 2017 / Revised: 27 November 2017 / Accepted: 28 November 2017 / Published: 7 December 2017
(This article belongs to the Collection Nanomedicine)
Full-Text   |   PDF [265 KB, uploaded 7 December 2017]


Background: Cancer remains a leading cause of death in companion animals. In human medicine, liposomes and nanoparticles have been extensively investigated as drug delivery systems (DDS) for anticancer agents due to their ability to target cancerous cells and reduce the negative side effects of free cytostatic drugs. In this review, the authors discuss the results of clinical trials using liposomes and polymer-based nanoparticles as DDS to improve cancer treatment in dogs and cats, indicating which ones seem worth further evaluation. The authors then overview ongoing animal cancer clinical trials, evaluating nano-DDS registered on the American Veterinary Medical Association Animal Health Studies Database. Finally, the authors indicate the nano-drugs that require further in vivo evaluation based on the encouraging results obtained from in vitro studies. Conclusions: Liposomes have been the most investigated nano-DDS in veterinary medicine. The lack of cardiotoxicity of the commercially available liposomal doxorubicin (Doxil/Caelyx) suggests it should be used in dogs with cardiac disorders, rather than using free doxorubicin. Cisplatin-incorporated hyaluronic acid nanoparticles, nanocrystals of cisplatin, and paclitaxel are the most promising nano-drugs for potent applications in treating various canine cancers (e.g. oral melanoma, oral sarcoma, and anal gland adenocarcinoma) and their translation into the treatment of human diseases. View Full-Text
Keywords: cancer; chemotherapy; drug delivery; liposomes; nanoparticles; veterinary medicine cancer; chemotherapy; drug delivery; liposomes; nanoparticles; veterinary medicine
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Zabielska-Koczywąs, K.; Lechowski, R. The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats. Molecules 2017, 22, 2167.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top